Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation — molecular dynamics study

被引:0
|
作者
Zahra Motamedi
Hassan Rajabi-Maham
Maryam Azimzadeh Irani
机构
[1] Shahid Beheshti University,Faculty of Life Sciences and Biotechnology
来源
Journal of Molecular Modeling | 2021年 / 27卷
关键词
Heterodimer; EGFR; ErbB2; Glycosylation; Molecular dynamics simulations;
D O I
暂无
中图分类号
学科分类号
摘要
ErbB family of receptor tyrosine kinases play significant roles in cellular differentiation and proliferation. Mutation or overexpression of these receptors leads to several cancers in humans. The family has four homologous members including EGFR, ErbB2, ErbB3, and ErbB4. From which all except the ErbB2 bind to growth factors via the extracellular domain to send signals to the cell. However, dimerization of the ErbB receptor occurs in extracellular, transmembrane, and intracellular domains. The ErbB receptors are known to form homodimers and heterodimers in the active form. Heterodimerization increases the variety of identified ligands and signaling pathways that can be activated by these receptors. Furthermore, glycosylation of the ErbB receptors has shown to be critical for their stability, ligand binding, and dimerization. Here, atomistic molecular dynamics simulations on the glycosylated and unglycosylated heterodimer showed that the EGFR-ErbB2 heterodimer is more stable in its dynamical pattern compared to the EGFR-EGFR homodimer. This increased stability is regulated by maintaining the dimeric interface by the attached glycans. It was also shown that the presence of various glycosylation sites within the ErbB2 growth factor binding site leads to occlusion of this site by the glycans that inhibit ligand binding to ErbB2 and participate in further stabilization of the heterodimer construct. Putting together, glycosylation seems to promote the heterodimer formation within the ErbB family members as the dominant molecular mechanism of activation for these receptors.
引用
收藏
相关论文
共 16 条
  • [1] Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study
    Motamedi, Zahra
    Rajabi-Maham, Hassan
    Azimzadeh Irani, Maryam
    JOURNAL OF MOLECULAR MODELING, 2021, 27 (12)
  • [2] Cancer regulator EGFR-ErbB4 heterodimer is stabilized through glycans at the dimeric interface
    Zahra Motamedi
    Mehri Shahsavari
    Hassan Rajabi-Maham
    Maryam Azimzadeh Irani
    Journal of Molecular Modeling, 2022, 28
  • [3] Cancer regulator EGFR-ErbB4 heterodimer is stabilized through glycans at the dimeric interface
    Motamedi, Zahra
    Shahsavari, Mehri
    Rajabi-Maham, Hassan
    Irani, Maryam Azimzadeh
    JOURNAL OF MOLECULAR MODELING, 2022, 28 (12)
  • [4] RPN2 promotes colorectal cancer cell proliferation through modulating the glycosylation status of EGFR
    Li, Haiping
    Al-Japairai, K.
    Tao, Yong
    Xiang, Zheng
    ONCOTARGET, 2017, 8 (42) : 72633 - 72651
  • [5] SANGUINARINE PROMOTES OVARIAN CANCER CHEMOSENSITIVITY TO CISPLATIN BY BLOCKING THE EGFR/ERBB2 SIGNALING PATHWAY
    Chen, Lin
    Yang, Ting
    Zhao, Xinyuan
    ACTA MEDICA MEDITERRANEA, 2023, 39 (02): : 481 - 486
  • [6] First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects
    Wang, Meng-na
    Kuang, Yun
    Gong, Li-ying
    Hua, Ye
    Pei, Qi
    Guo, Cheng-xian
    Cao, Yu
    Huang, Jie
    Yang, Guo-ping
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1826 - 1835
  • [7] Splitting of α-Helical Structure as Molecular Basis for Abolishing an Amyloid Formation by Multiple Glycosylation: A Molecular Dynamics Simulation Study
    Choi, Youngjin
    Cho, Eunae
    Jung, Seunho
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2016, 37 (07) : 1159 - 1162
  • [8] In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation
    Ibraheim, Mona H.
    Maher, Ibrahim
    Khater, Ibrahim
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2024, 196 (11) : 8332 - 8365
  • [9] Breast Cancer Molecular Class ERBB2: Preponderance of Tumors With Apocrine Differentiation and Expression of Basal Phenotype Markers CK5, CK5/6, and EGFR
    Bhargava, Rohit
    Beriwal, Sushil
    Striebel, Joan M.
    Dabbs, David J.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2010, 18 (02): : 113 - 118
  • [10] Understanding the formation of nanorods on hematite (α-Fe2O3) in the presence of surfactants: A molecular dynamics simulation study
    Kaur, Kanwalpreet
    Singh, Gurinder
    Kaura, Aman
    JOURNAL OF MOLECULAR LIQUIDS, 2020, 316